摘要
上皮性卵巢癌(EOC)是妇科恶性肿瘤中最致命的疾病。尽管对卵巢癌的生物学认识和疗效上都有所提高,在过去的二十年里,卵巢癌患者的生存率没有改善。由于化疗耐药性的发展,晚期患者经常复发。最近在体内和体外研究表明对这种耐药性的机制的了解,包括微核糖核酸(miRNA,miR)在耐药过程的潜在作用。在这篇综述中,我们概述了当前上皮性卵巢癌与miRNA相关的化疗耐药的治疗靶点,讨论其潜在的治疗价值和miRNA影响化疗耐药的进展和逆转的分子机制。
关键词: 卵巢癌、复发、耐药性、微核糖核酸靶点,癌基因,肿瘤抑制因子。
图形摘要
Current Cancer Drug Targets
Title:Mechanisms and Therapeutic Targets of microRNA-associated Chemoresistance in Epithelial Ovarian Cancer
Volume: 16 Issue: 5
Author(s): Lingyun Zhang, Lubna Nadeem, Kristin Connor, Guoxiong Xu
Affiliation:
关键词: 卵巢癌、复发、耐药性、微核糖核酸靶点,癌基因,肿瘤抑制因子。
摘要: Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Despite increasing knowledge of ovarian cancer biology and advances in treatment efficacy, the survival rate of patients with EOC has not improved over the past two decades. Patients with an advanced disease often relapse due to the development of chemoresistance. Recent in vivo and in vitro studies have shown insight into the mechanisms of such drug resistance, including a potential role for microRNAs (miRNA, miR) in the process of chemoresistance. In this review, we provide an overview of current therapeutic targets of miRNA-associated chemoresistance in EOC and discuss potential therapeutic values and molecular mechanisms by which miRNAs influence the development and reversal of chemoresistance.
Export Options
About this article
Cite this article as:
Lingyun Zhang, Lubna Nadeem, Kristin Connor, Guoxiong Xu , Mechanisms and Therapeutic Targets of microRNA-associated Chemoresistance in Epithelial Ovarian Cancer, Current Cancer Drug Targets 2016; 16 (5) . https://dx.doi.org/10.2174/1568009616666160404121105
DOI https://dx.doi.org/10.2174/1568009616666160404121105 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical and <i>In Silico</i> Outcomes of the Expression of miR-130a-5p and miR-615-3p in Tumor Compared with Non-Tumor Adjacent Tissues of Patients with BC
Anti-Cancer Agents in Medicinal Chemistry Emerging Multi-cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT
Current Cancer Drug Targets Design of Curcumin loaded Cellulose Nanoparticles for Prostate Cancer
Current Drug Metabolism Gestational Trophoblastic Neoplasia, an Ancient Disease: New Light and Potential Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Encountering and Advancing Through Antiangiogenesis Therapy for Gliomas
Current Pharmaceutical Design On the Nature of the Tumor-Initiating Cell
Current Stem Cell Research & Therapy Chlorella vulgaris Induces Apoptosis of Human Non-Small Cell Lung Carcinoma (NSCLC) Cells
Medicinal Chemistry The Impact of Thrombopoietin on Clinical Practice
Current Pharmaceutical Design Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)
Current Signal Transduction Therapy Fanconi Anemia DNA Repair Pathway as a New Mechanism to Exploit Cancer Drug Resistance
Mini-Reviews in Medicinal Chemistry Stilbenes and Xanthones from Medicinal Plants as Potential Antitumor Agents
Current Bioactive Compounds Tissue Distribution and Pharmacodynamics: A Complicated Relationship
Current Drug Metabolism Nanotechology-Based Strategies to Enhance the Efficacy of Photodynamic Therapy for Cancers
Current Drug Metabolism The Effects of Mesenchymal Stem Cells in Craniofacial Tissue Engineering
Current Stem Cell Research & Therapy Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
Current Medicinal Chemistry MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Current Drug Targets Heterocyclic Chalcone Analogues as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Synthetic Methods of Quinoline Derivatives as Potent Anticancer Agents
Mini-Reviews in Medicinal Chemistry The Role of Tumor Suppressor DLC-1: Far From Clear
Anti-Cancer Agents in Medicinal Chemistry New Perspectives on Machine Learning in Drug Discovery
Current Medicinal Chemistry